Allarity Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Allarity Therapeutics, Inc. (ALLR) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-30
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2024-12-31 was $65.00K, a 21.69% decline year-over-year.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2024-09-30 was -$432.00K.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2024-06-30 was $0.00.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2024-03-31 was -$14.00K.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$381.00K, a 559.04% decline from fiscal 2023.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was $83.00K.
- Allarity Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$1.61M, a 8160.00% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$367.00K derived: sum of 2 quarters · filed 2026-03-30 | -$367.00K derived: sum of 3 quarters · filed 2026-03-30 | -$381.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$432.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$432.00K derived: sum of 2 quarters · filed 2024-11-14 | -$446.00K 10-Q · filed 2024-11-14 | -$363.00K derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$14.00K 10-Q · filed 2024-08-05 | $69.00K derived: sum of 3 quarters · filed 2025-03-31 | |||
| 2024-03-31 | -$14.00K 10-Q · filed 2024-05-14 | $69.00K derived: sum of 2 quarters · filed 2025-03-31 | ||||
| 2023-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $83.00K 10-K · filed 2025-03-31 | $97.00K 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | |||||
| 2022-12-31 | -$270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$389.00K derived: sum of 2 quarters · filed 2024-03-08 | -$385.00K derived: sum of 3 quarters · filed 2024-03-08 | -$1.61M 10-K · filed 2024-03-08 | ||
| 2022-09-30 | -$119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$115.00K derived: sum of 2 quarters · filed 2023-11-14 | -$1.34M 10-Q · filed 2023-11-14 | -$1.47M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.22M 10-Q · filed 2023-08-14 | -$1.35M derived: sum of 3 quarters · filed 2023-08-14 | -$1.18M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$1.23M 10-Q · filed 2023-05-11 | -$1.35M derived: sum of 2 quarters · filed 2023-05-11 | -$1.19M derived: sum of 3 quarters · filed 2023-05-11 | -$1.24M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $42.00K derived: sum of 2 quarters · filed 2023-03-13 | -$13.00K derived: sum of 3 quarters · filed 2023-03-13 | $20.00K 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $113.00K derived: sum of 2 quarters · filed 2022-11-14 | $146.00K 10-Q · filed 2022-11-14 | -$475.00K 10-Q · filed 2021-11-23 | $128.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | -$22.00K 10-Q · filed 2022-10-07 | -$40.00K derived: sum of 3 quarters · filed 2022-10-07 | |||
| 2021-03-31 | $33.00K 10-Q · filed 2022-05-27 | $15.00K derived: sum of 2 quarters · filed 2022-05-27 | ||||
| 2020-12-31 | -$18.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $165.00K 10-K · filed 2022-05-17 | ||||
| 2020-09-30 | $183.00K 10-Q/A · filed 2022-05-17 | -$948.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |